ESC 365 - Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial

ESC Premium Access

Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial

Session: Hot Line: Late-Breaking Clinical Trials 2

Topic: Atrial fibrillation (AF)

Speaker: Professor M. Ezekowitz (Philadelphia, US)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Michael Ezekowitz

Thomas Jefferson University Hospital, Philadelphia (United States of America)

4 presentations

0 follower

17 more presentations in this session

SPYRAL HTN OFF-MED Study

Speaker: Professor M. Boehm (Homburg, DE)

Discussant review: SPYRAL HTN OFF-MED Study

Speaker: Professor B. Williams (London, GB)

Panel discussion.

Discussant review:Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial

Speaker: Professor J. Nielsen (Aarhus, DK)

Panel discussion.

Access the full session

Hot Line: Late-Breaking Clinical Trials 2

Speakers: Professor M. Ezekowitz, Professor M. Boehm, Professor B. Williams, Professor J. Nielsen

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources